**Name of Journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 63118

**Manuscript Type:** REVIEW

**Individualized treatment options for patients with non-cirrhotic and cirrhotic liver disease**

Hartl L *et al*. Personalized therapy in MAFLD/NASH

Lukas Hartl, Joshua Elias, Gerhard Prager, Thomas Reiberger, Lukas W Unger

**Lukas Hartl, Thomas Reiberger,** Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna A-1090, Austria

**Lukas Hartl, Thomas Reiberger,** Vienna Hepatic Hemodynamic Lab, Medical University of Vienna, Vienna A-1090, Austria

**Joshua Elias, Lukas W Unger,** Cambridge Institute of Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge CB2 0AW, United Kingdom

**Joshua Elias,** Division of Gastroenterology and Hepatology, Department of Medicine, University of Cambridge, Addenbrooke’s Hospital, Cambridge CB2 0QQ, United Kingdom

**Gerhard Prager, Lukas W Unger,** Division of Visceral Surgery, Department of General Surgery, Medical University of Vienna, Vienna A-1090, Austria

**Author contributions:** Hartl L, Elias J and Unger LW performed literature review, prepared figures and tables and wrote the manuscript; Prager G and Reiberger T gave important intellectual input; all authors contributed intellectually, critically revised the manuscript and approved the final version of the manuscript.

**Supported by** Austrian Science Fund FWF, No. J4396; and Wellcome Trust PhD Fellowship for Clinicians, No. UNS59491.

**Corresponding author: Lukas W Unger, MD, PhD, Doctor,** Division of Visceral Surgery, Department of General Surgery, Medical University of Vienna, Währinger Gürtel 18-20, Vienna A-1090, Austria. lukas.unger@meduniwien.ac.at

**Received:** January 24, 2021

**Revised:** March 19, 2021

**Accepted:** April 25, 2021

**Published online:**

**Abstract**

The obesity pandemic has led to a significant increase in patients with metabolic dysfunction-associated fatty liver disease (MAFLD). While dyslipidemia, type 2 diabetes mellitus and cardiovascular diseases guide treatment in patients without signs of liver fibrosis, liver related morbidity and mortality becomes relevant for MAFLD’s progressive form, non-alcoholic steatohepatitis (NASH), and upon development of liver fibrosis. Statins should be prescribed in patients without significant fibrosis despite concomitant liver diseases but are underutilized in the real-world setting. Bariatric surgery, especially Y-Roux bypass, has been proven to be superior to conservative and/or medical treatment for weight loss and resolution of obesity-associated diseases, but comes at a low but existent risk of surgical complications, reoperations and very rarely, paradoxical progression of NASH. Once end-stage liver disease develops, obese patients benefit from liver transplantation (LT), but may be at increased risk of perioperative infectious complications. After LT, metabolic comorbidities are commonly observed, irrespective of the underlying liver disease, but MAFLD/NASH patients are at even higher risk of disease recurrence. Few studies with low patient numbers evaluated if, and when, bariatric surgery may be an option to avoid disease recurrence but more high-quality studies are needed to establish clear recommendations. In this review, we summarize the most recent literature on treatment options for MAFLD and NASH and highlight important considerations to tailor therapy to individual patient’s needs in light of their risk profile.

**Key Words:** Metabolic dysfunction-associated fatty liver disease; Non-alcoholic fatty liver disease; Portal hypertension; Cirrhosis; Bariatric surgery; Metabolism

Hartl L, Elias J, Prager G, Reiberger T, Unger LW. Individualized treatment options for patients with non-cirrhotic and cirrhotic liver disease. *World J Gastroenterol* 2021; In press

**Core Tip:** No single therapy fits all needs, sometimes resulting in complex clinical decision making. While some etiologies can distinctly be characterized, a multifactorial disease such as metabolic dysfunction-associated fatty liver disease requires thorough assessment of comorbidities and severity of concomitant fibrosis to assess a patient’s overall risk. While (guided) physical exercise is usually safe and well tolerated and strict treatment of diabetes and dyslipidemia is warranted, patients often fail to change their lifestyle, resulting in life-long drug dependency for comorbidities. Bariatric surgery has therefore become a valid option for obese patients and should be offered in eligible patients before liver fibrosis develops.

**INTRODUCTION**

In recent decades, the fractional contribution of different etiologies to the total burden of chronic liver disease (CLD) has shifted. On the one hand these changes are driven by a decrease in hepatitis C virus (HCV) related morbidity which has decreased by 40% in the United States[1] and led to HCV becoming a less common indication for liver transplantation (LT) in Europe[2], a trend that will likely be seen globally in the near future. On the other hand there is a steady and significant increase in non-alcoholic fatty liver disease (NAFLD), overall resulting in a relative shift of CLD etiologies, and an even further absolute increase in NAFLD related morbidity. While HCV related liver disease is a domain of hepatologists and transplant units, NAFLD, recently proposed to be re-named metabolic dysfunction-associated fatty liver disease (MAFLD)[3,4], is associated with extrahepatic diseases, such as central obesity[5], sleep apnea, type 2 diabetes mellitus (T2DM), cardiovascular diseases, and bone and joint disorders, all contributing to relevant morbidity and affecting different specialties[6].

Mirroring the obesity pandemic and in line with CLD etiology shifts, the number of LTs due to non-alcoholic steatohepatitis (NASH)-related cirrhosis, which results from progression of MAFLD, has markedly increased[1,2,7,8], with NASH already representing the second most frequent cause for LT in the United States[1,9,10]. In addition, the prevalence of hepatocellular carcinoma due to NASH is also rapidly increasing[2,8,11,12], probably resulting in an even higher need for LT due to MAFLD/NASH in the future. Thus, this review summarizes current treatment options in MAFLD, tailored to individual patient’s disease stage in light of the most recent evidence. We provide a short overview of the core messages in Figure 1 and highlight several studies on the most important topics, which are discussed in further detail below, in Table 1.

**NAFLD/MAFLD AND THE METABOLIC SYNDROME**

MAFLD is commonly considered a hepatic manifestation of the metabolic syndrome (MS)[13,14]. It is defined as excessive hepatic fat accumulation with insulin resistance, steatosis in > 5% of hepatocytes in histological analysis (or > 5.6% by quantitative fat/water-selective magnetic resonance imaging or proton magnetic resonance spectroscopy), and exclusion of secondary causes as well as alcoholic fatty liver disease, *e.g.* daily alcohol consumption of < 30 g for men and < 20 g for women, commonly resulting in difficulties to differentiate between alcoholic fatty liver disease and MAFLD in retrospective studies[15]. The severity of MAFLD can vary, ranging from simple steatosis[16] to NASH with chronic inflammation and fibrosis to liver cirrhosis[17,18]. Unfortunately, NASH diagnosis can, to date, only be made histologically by presence of macrovesicular steatosis, ballooning degeneration of hepatocytes, scattered inflammation, and Mallory-Denk bodies[19]. This limitation has led to the search for alternative non-invasive diagnostic procedures that avoid the need for liver biopsy, reviewed by *e.g.* Paternostro *et al*[20], to identify patients that are most likely to suffer from liver-related complications[21].

Before significant fibrosis develops, however, several factors contribute to the development of MAFLD, such as nutrition[22-24], insulin resistance[25,26], adipokines[27], gut microbiota[28,29], and genetic as well as epigenetic factors[30,31]. The close association of energy metabolism and fatty liver disease is illustrated by the fact that MAFLD patients suffer from increased risk for cardiovascular disease[32,33], T2DM[34-36], as well as chronic kidney disease[37].According to a meta-analysis by Younossi *et al*[38], 51.3% of NAFLD and 81.8% of NASH patients are obese, 22.5% and 43.6% suffer from T2DM, and 69.2% and 72.1% from dyslipidemia, respectively[38]. This indicates that neither of the diseases should be addressed in an isolated fashion as they impact each other and contribute to disease progression. Thus, MAFLD patients must be seen as metabolically multimorbid, which is reflected by increased cardiovascular mortality compared to liver-related mortality in individuals without significant liver fibrosis[38]. Once liver fibrosis develops, however, liver-related mortality becomes more relevant. Recent evidence from high quality studies suggests that concomitant fibrosis, and especially cirrhosis, rather than NASH *per se* significantly increase liver-related morbidity and mortality[39-41]. Thus, well-established tools such as transient elastography with adapted cutoff values may allow risk stratification, and identification of significant fibrosis should result in state-of-the-art therapy with a liver-centered approach[20].

**THERAPEUTIC OPTIONS IN MAFLD/NASH**

As mentioned above, the first step in risk stratification for individual patients should be assessment of presence/absence of liver fibrosis. In case of absence of liver fibrosis, regardless of the underlying etiology, removal of the damaging agent is vital to prevent development of fibrosis and subsequent portal-hypertensive decompensation events. In MAFLD, lifestyle modifications should be seen as cornerstone of causative treatment, as obesity, high-fat diet and physical inactivity are strongly associated with development as well as progression of the disease[42]. Unfortunately, to date no pharmacological treatment has specifically been approved for MAFLD, and current trials on drugs for MAFLD or NASH target mostly metabolic pathways to improve insulin resistance or dyslipidemia. As of 2018, more than 300 substances were in clinical trials for MAFLD/NASH[43,44]. However, the majority of trials have fallen short of proving efficacy and the most effective, to date, are repurposed drugs such as statins[45]. In terms of newly developed compounds, a recent prospective, placebo controlled study of obeticholic acid (OCA), which is a farnesoid X receptor agonist that was shown to decrease hepatic fibrosis and reduce inflammation in preclinical studies, found that OCA improved fibrosis severity in patients with NASH[46]. Of note, however, complete NASH resolution was not more common in patients treated with either OCA dosing intensity (placebo: 8%; OCA 10 mg daily: 11%; OCA 25 mg daily, 12%), and overall fibrosis improvement was still only achieved in approximately 1/4 patients (fibrosis improvement of ≥ 1 stage: Placebo: 12%, OCA 10 mg daily: 18%, and OCA 25 mg daily: 23%), highlighting the complexity of NASH treatment. Nevertheless, with this first successful trial, a broader repertoire of pharmacological agents will hopefully be available in the near future.

**Obesity Management, Diet and Exercise**

Adequate therapy for obesity is of utmost relevance, as obesity *per se* independently increases the risk for cardiovascular disease[47] and independently predicted clinical decompensation in a subgroup-analysis of a placebo-controlled trial assessing beta blockers for the prevention of esophageal varices, irrespective of the underlying etiology[48]. Furthermore, morbidly obese patients, defined as patients with a body mass index (BMI) ≥ 40 kg/m², have a significantly higher LT waiting list mortality, and benefit more from LT according to Schlansky *et al*[49], although the cause of death was not available from this United Network for Organ Sharing registry based study[49].

Lifestyle interventions are crucial, as a weight loss of 7%-10% of initial body weight is already associated with histological improvement in MAFLD with a reduction of steatosis, ballooning and lobular inflammation[50,51]. Even lower rates of sustained weight loss (about 5%) can decrease steatosis[52], liver enzymes[53] and the risk of developing T2DM[54]. Remission of MAFLD due to lifestyle interventions has also been demonstrated in non-obese patients with MAFLD[55] despite the fact that the underlying causes of lean MAFLD are unclear[56]. Guidelines suggest that the lifestyle modifications recommended to patients with MAFLD should be structured and include prescribed physical activity including resistance training, a calorie restricted “Mediterranean” diet, avoidance of high fructose foods and avoidance of excess alcohol consumption. In addition, smoking cessation is important to improve the cardiovascular risk profile.

Both, diet and exercise are safe in patients with compensated cirrhosis[57], have been shown to be highly effective for treatment of risk factors (cardiovascular disease and T2DM, respectively)[50,51,58], and lower hepatic portal pressure in overweight CLD patients regardless of etiology[57]. Importantly, however, recommendations for weight loss in obese NAFLD/NASH patients with cirrhosis are more cautious, as uncontrolled weight loss in decompensated patients may worsen sarcopenia and frailty[47]. Thus, diligent planning of diet and exercise is required to ensure weight loss with an adequate intake of nutrients, especially proteins. It should also be considered to be mandatory to investigate whether patients have an indication for non-selective beta-blocker (NSBB) prophylaxis against variceal hemorrhage before enrollment into an exercise program, as NSBB counteract exercise-mediated increases of hepatic venous pressure gradient (HVPG)[59,60].

Importantly, evidence from a recently published randomized controlled trial suggests that once-weekly subcutaneous semaglutide leads to sustained and clinically relevant weight reduction (mean weight loss -14.9% in semaglutide treated patients compared to -2.4% in the placebo group, respectively), with a more pronounced amelioration of cardiometabolic risk factors and patient-reported physical functioning in non-diabetic obese individuals[61]. Thus, these first encouraging results suggest that more effective pharmacological therapies may become available in the future.

**Dyslipidemia**

Dyslipidemia is a major risk factor for the development and progression of atherosclerotic cardiovascular disease[62] and often presents as a comorbidity in patients with CLD[63]. Lipid profiles can be altered by liver diseases due to impaired cholesterol synthesis, leading to a seemingly improved lipid profile with CLD disease progression[63]. Nevertheless, pharmacologically, 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibition *via* statins is by far the most important treatment option for dyslipidemia, leading to a decrease of systemic levels of low-density lipoprotein (LDL) cholesterol, as well as other pleiotropic effects[64]. Generally, statins are well-tolerated, however, 10%-15% of patients experience adverse events such as myalgia with or without increase of creatinine kinase[64,65]. From a liver perspective, the long-standing dogma that statin therapy is contraindicated in patients with CLD has been proven to be outdated[63]. We and others could show that in real-life settings, statins are underutilized in CLD patients[63,66]. Despite clear indications for statin utilization to reduce cardiovascular morbidity and mortality, outlined in the American College of Cardiology/American Heart Association guidelines, we found that 34.2% of patients with non-advanced CLD and 48.2% patients with advanced CLD did not receive statins despite having a clear indication, and we found that guideline-conformed statin use translated to improved overall survival of compensated CLD, but not decompensated CLD patients[63]. Others have found that statins directly influence liver-specific outcome by lowering the risk of hepatic decompensation[67,68], potentially by reducing HVPG, improving hepatocyte function[69] and ameliorating sinusoidal endothelial dysfunction[70,71], overall indicating that statins should at least be prescribed in patients with non-cirrhotic CLD with cardiovascular risk profiles. In a small pilot trial, simvastatin did improve lipid profiles, but did not affect steatosis levels and necroinflammation in 16 NASH patients, but also did not do any harm although results have to be interpreted with caution due to the small sample size[72].

Overall, most studies have found that, if adhering to available guidelines for statin initiation in patients without decompensated liver disease, adverse events rates are low, and the majority of studies reported beneficial effects of statins in compensated CLD, irrespective of CLD etiology[73-79].

**T2DM**

An association between MAFLD and T2DM is well-established[80]. MAFLD and T2DM commonly coexist[81,82] and even in T2DM patients with normal serum alanine aminotransferase levels the prevalence of liver steatosis is high[83]. Conversely, many studies demonstrated high rates of NASH in T2DM patients[84-86], and it has also been shown that T2DM is strongly associated with liver fibrosis[87-90]. Two studies based on liver histology found that MAFLD patients with T2DM commonly develop severe fibrosis, namely in 40.3% and 41.0%, respectively[85,86]. Other studies, assessing liver stiffness by transient elastography, showed that 17.7% and 5.6% of diabetic patients suffer from advanced fibrosis[91,92]. This is of high importance, as liver fibrosis is the crucial factor associated with long-term outcome in MAFLD patients[93,94] and indeed, MAFLD and T2DM synergistically lead to an increased rate of adverse outcomes[95] including increased liver-related and overall mortality[96,97].

Thus, regulation of insulin sensitivity is essential in patients with MAFLD and there is growing evidence for pharmacological treatments that are effective for treating both, T2DM and MAFLD[93]. Pioglitazone, an insulin sensitizer that stimulates adipocyte differentiation by peroxisome proliferator-activated receptor *g* agonism[98], has for example shown beneficial effects on NAFLD. Pioglitazon reduced biopsy-assessed NAFLD severity and liver fat content in patients with[99], but also without T2DM[100] upon short-term treatment. Moreover, a randomized controlled trial showed significantly more frequent resolution of NASH in patients treated with pioglitazone (34%) than with placebo (19%)[101]. However, fibrosis was not ameliorated and also insulin resistance only partially decreased, which may be attributable to the low administered pioglitazone dose of 30 mg *per* day[93]. In another randomized controlled trial in NASH patients with T2DM or prediabetes, 45 mg pioglitazone *per* day improved histological NAFLD activity score, fibrosis and insulin sensitivity[102]. Importantly, side effects of pioglitazone include weight gain, fluid retention with increased risk of congestive heart failure, as well as decrease of bone mineral density, resulting in atypical fractures[98], which has to be actively screened for when prescribing pioglitazone in MAFLD patients.

Glucagon-like peptide-1 (GLP-1) receptor agonists also represent a valuable treatment option for patients with MAFLD, as they improve glucose-dependent insulin secretion, but also promote weight loss and lower liver transaminase levels[103]. In a pilot trial, subcutaneous liraglutide decreased liver fat content and was associated with more frequent NASH resolution, as compared to placebo (39% *vs* 9%)[104]. In contrast, metformin, the first-line T2DM medication, does not consistently improve hepatic steatosis or inflammation in patients with NASH[105-109]. Overall, however, antidiabetic drugs show great promise for treatment of MAFLD/NASH (and weight loss) but more adequately designed randomized controlled trials, are needed.

**Bariatric Surgery and MAFLD/NASH regression**

As mentioned above, the co-existence of several metabolic diseases, summarized as MS, has led to the development of invasive/surgical treatment options. While bariatric surgery was a niche phenomenon for several years, its benefit with regards to weight loss and subsequent improvement of insulin resistance/T2DM is established by now[110]. Moreover, due to improved success rates with regards to weight loss compared to conservative approaches, bariatric surgery patients have a significantly better 10-year[111] and 20-year overall survival than comparable patients that were treated conservatively, although, despite this improvement, their life expectancy is still lower than from the general population[112]. Recent evidence suggests that the major benefit results from weight loss itself and is not attributed to any other metabolic effects of bypass surgery. These assumptions come from a study that compared patients with Y-Roux bypass to patients who lost the same amount of weight by dietary/Lifestyle changes and observed similar effects, indicating that bypass surgery *per se* does not alter metabolism more than weight loss itself[113]. In terms of liver-specific outcomes, bariatric surgery has not been taken into account as treatment option in several meta-analyses on NASH resolution, despite available properly designed studies. In general, bariatric surgery results in resolution of NASH in the majority of patients (85% in[114], with 64.2% of patients undergoing bypass surgery and 5.5% of sleeve gastrectomies) and regression of fibrosis[114]. However, not all procedures are equal, and Y-Roux bypass is considered to be most effective strategy for sustainable weight loss to date[115]. A recent hierarchical network meta-analysis included 48 high quality trials and found that pioglitazone and Y-Roux gastric bypass had the best effect on improvement of the NAFLD Activity Score[116], suggesting a causative connection between glucose metabolism and fatty liver development. While bariatric surgery impacts on NASH, NASH and liver fibrosis, expectedly, also impact on postoperative outcome after bariatric surgery[117]. This, again, highlights that metabolic diseases do not exist as isolated diseases but must be treated together. Importantly, bariatric surgery is only offered to severely obese patients, while the general population is often overweight, but not obese, and thus not eligible for surgery, warranting further basic research studies disentangling the mechanisms of MAFLD/NASH development. Noteworthy, a very small fraction of patients develops NASH or suffers from NASH/fibrosis aggravation after bariatric surgery, requiring adequate post-operative care for early detection of complications and further emphasizing the need for ongoing research[118]. Considering that bariatric surgery is increasingly utilized, prospective studies answering the remaining questions on the connection of insulin resistance, fatty liver, and fibrosis progression should become available in the near future.

**Obesity and MAFLD/NASH Before and After LT**

In general, patients with cirrhosis/end-stage liver disease should be managed according to available guidelines for the treatment of portal hypertension, as liver-related mortality is the main cause of death in end-stage liver disease, with special regard to the above-mentioned pitfalls in obese patients[119]. According to the 2018 Organ Procurement and Transplantation Network/Scientific Registry of Transplant Recipients LT report, 36.9% of adult patients undergoing LT were obese [BMI (30 kg/m2)] including 14.8% with a BMI of more than 35 (kg/m²)[120]. Despite the caveat that BMI is not an ideal parameter in patients with end-stage liver disease due to ascites, these data still highlight obesity as an important comorbidity in LT. Due to increasing experience in treatment of these patients, morbid obesity [BMI (40 kg/m2)] is no longer seen as a contraindication for LT[47], as morbidly obese patients clearly profit from LT[49,121]. However, specific challenges include technical difficulties during surgery, as well as higher morbidity in the postoperative course, especially due to an increased risk of infections[122-125]. Ultimately, these challenges translate to an increased 30 d mortality[126]. However, outcomes seem to be gradually improving, as Schlansky *et al*[49] could detect impaired post-OP survival before but not after 2007[49]. In terms of long-term outcomes of NASH LT recipients, survival rates are comparable to other etiologies despite the fact that Malik *et al*[127] found an alarming 50% 1-year mortality rate among obese NASH patients 60 years old with T2DM and arterial hypertension[127]. Thus, pre-transplant work-up warrants extensive risk-benefit evaluation on a case-to-case basis before listing for LT to avoid unexpected complications[128].

Following LT, weight gain is common irrespective of the underlying CLD and type of transplanted organ. In general, approximately one in three LT recipients becomes overweight or obese within 3 years[129] and decreased physical activity, excess energy intake and older age favor development of sarcopenic obesity with increased risk of cardiovascular and metabolic comorbidities[130,131]. Although a clear research agenda has been set out in 2014 by the American Society for Transplantation[132], outcome measures are heterogeneous, and liver transplant recipients are underrepresented in these studies. A recent review of 2 observational and 3 randomized controlled trials by Dunn *et al*[133] reported that exercise intervention groups generally performed better at strength testing, energy expenditure in metabolic equivalents, and peak or maximal oxygen uptake[133]. An even more recently published prospective study reported that financial incentives resulted in more patients achieving their target of > 7000 steps *per* day, which, however, did not translate into less weight gain[134]. Another study using a smartphone app found that 35% of participants significantly increased their physical performance, but did not report whether this translated into an outcome benefit[135]. Thus, despite positive impacts on surrogate parameters, little to no high-quality evidence is available whether exercise directly affects overall survival or liver related outcome after transplantation.

Similar to a lack of high-quality data on exercise programs, more prospective studies are needed to evaluate the effect of bariatric surgery at the time of LT. Recently, a meta-analysis of available studies on bariatric surgery during or after LT found that sleeve gastrectomy is the most commonly performed procedure and that bariatric surgery related morbidity and mortality rates were 37% and 0.6%, respectively. Regarding outcome parameters, BMI was significantly lower in bariatric surgery patients 2 years after LT, with significantly lower rates of arterial hypertension and diabetes mellitus[136]. Of note, however, prospective randomized studies are needed to compare whether the benefits outweigh the risks in terms of overall outcome, which poses several difficulties in this setting.

In addition to weight gain, prevalence of dyslipidemia is high in the post-LT setting and affects approximately 40%-70%[137]. Partly, dyslipidemia and impaired glucose tolerance are metabolic adverse effects of immunosuppressants such as calcineurin inhibitors, mammalian target of rapamycin inhibitors and corticosteroids[8,138]. Thus, statins are commonly used after LT, however, data regarding statin therapy and potential effects on portal pressure and hepatocyte function in the post-transplant setting are scarce and a clear guideline for post-transplant statin use is not available[138]. Nevertheless, it has been shown that dyslipidemia is linked to increased morbidity and mortality in LT recipients and recently, a study by Patel *et al*[139] demonstrated good tolerance of statins and a survival benefit of statin-treated patients after LT, favoring statin use also in this setting[139]. Moreover, experimental studies in rats have demonstrated a graft-protecting effect of statins, when added to the cold storage solution[140,141]. Overall, prospective high-quality studies defining cut-offs are lacking, but available evidence suggests beneficial effects of statins in the post-LT setting.

Despite ameliorated glycogen synthesis, only few patients exhibit improved insulin sensitivity after LT[8]. Contrarily, 10% to 30% of patients suffer from new onset T2DM after LT, which is linked to the use of corticosteroids and tacrolimus[142,143]. In the immediate post-transplant period, insulin is considered the safest and most effective choice for anti-hyperglycemic therapy[144-147]. For the management of persistent T2DM after LT, however, evidence is scarce. A recent meta-analysis concluded that safety and efficacy cannot be concluded for various anti-hyperglycemic agents in the post-transplant setting, as the available studies are not of high enough quality[148]. Thus, anti-hyperglycemic therapy after the first-line metformin should be selected according to patient preference, as well as clinical characteristics such as presence of chronic kidney disease, heart failure or obesity[147,149].

**AUTHOR’S PERSPECTIVE**

MAFLD/NASH is a complex disease entity that poses challenges for clinical practice and requires interdisciplinary management for optimal patient care. In recent years, several novel concepts have been established, and bariatric surgery has been proven to be an effective treatment option. Additionally, recent trial results suggest that novel therapeutics, or repurposed drugs, may be effective to improve MAFLD or achieve sustainable weight loss and potentially secondary improvement of MAFLD/NASH. Thus, the multifactorial nature of the disease and the interconnectedness of different aspects require up-to-date knowledge, especially as more therapeutics will likely become available. These developments require an individualized treatment plan and should be based on patient’s preferences, as compliance is of utmost importance.

In patients with advanced CLD or end-stage NASH, eligibility assessment for LT should be conducted in due time. Once patients undergo orthotopic LT, metabolic comorbidities should be closely monitored and adequately treated. In the future, the special metabolic vulnerability of LT patients will become even more relevant, as NASH as indication of LT is rapidly increasing, emphasizing the importance of future trials in this special patient population.

**CONCLUSION**

With the growing obesity epidemic and the rising prevalence of MAFLD/NASH, management of patients with CLD has become quite complex. MAFLD/NASH patients are often multimorbid, exhibiting various features of the MS, which altogether increase the risk of cardiovascular morbidity and mortality. In the early stages of liver disease without signs of liver fibrosis (MAFLD), management of comorbidities guides the therapy, while in patients who develop NASH and liver fibrosis liver-related complications and mortality become relevant.

Unfortunately, there is a general lack of high-quality studies reporting important end points, such as fibrosis severity, which impedes comparability of the available results. Lifestyle interventions such as specific diets and exercise represent an etiological treatment for MAFLD/NASH patients and have been proven to be safe even for patients with cirrhosis and portal hypertension. Moreover, it has been shown that even moderate weight loss can lead to histological improvement, making lifestyle intervention an essential part of MAFLD/NASH management. Bariatric surgery is superior for weight loss of morbidly obese patients compared to conservative weight loss regimen, however, the risk of bariatric surgery is higher in patients with CLD and in some patients, severe liver dysfunction after bariatric surgery does occur.

Statins should be prescribed for all compensated patients with dyslipidemia or other risk factors like cardiovascular disease, but are heavily underutilized. While there is evidence that statin therapy is safe and also effective in MAFLD/NASH patients, large randomized controlled trials are still lacking. Concerning T2DM therapy, new anti-hyperglycemic agents such as pioglitazone or GLP-1 agonists are promising, but specific side effects may be detrimental and have to be considered. Metformin remains the first-line antihyperglycemic therapy.

Once end-stage liver disease has developed, obese patients benefit from LT, but also have increased perioperative risk, especially due to infections. After LT, metabolic complications are common. However, to date, there is little high-quality data concerning management of post-LT dyslipidemia and T2DM. Randomized controlled trials are needed to ensure the best possible care for these patient groups.

**REFERENCES**

1 **Cotter TG**, Charlton M. Nonalcoholic Steatohepatitis After Liver Transplantation. *Liver Transpl* 2020; **26**: 141-159 [PMID: 31610081 DOI: 10.1002/lt.25657]

2 **Adam R**, Karam V, Cailliez V, O Grady JG, Mirza D, Cherqui D, Klempnauer J, Salizzoni M, Pratschke J, Jamieson N, Hidalgo E, Paul A, Andujar RL, Lerut J, Fisher L, Boudjema K, Fondevila C, Soubrane O, Bachellier P, Pinna AD, Berlakovich G, Bennet W, Pinzani M, Schemmer P, Zieniewicz K, Romero CJ, De Simone P, Ericzon BG, Schneeberger S, Wigmore SJ, Prous JF, Colledan M, Porte RJ, Yilmaz S, Azoulay D, Pirenne J, Line PD, Trunecka P, Navarro F, Lopez AV, De Carlis L, Pena SR, Kochs E, Duvoux C; all the other 126 contributing centers (www.eltr.org) and the European Liver and Intestine Transplant Association (ELITA). 2018 Annual Report of the European Liver Transplant Registry (ELTR) - 50-year evolution of liver transplantation. *Transpl Int* 2018; **31**: 1293-1317 [PMID: 30259574 DOI: 10.1111/tri.13358]

3 **Eslam M,** Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, Zelber-Sagi S, Wai-Sun Wong V, Dufour JF, Schattenberg JM, Kawaguchi T, Arrese M, Valenti L, Shiha G, Tiribelli C, Yki-Järvinen H, Fan JG, Grønbæk H, Yilmaz Y, Cortez-Pinto H, Oliveira CP, Bedossa P, Adams LA, Zheng MH, Fouad Y, Chan WK, Mendez-Sanchez N, Ahn SH, Castera L, Bugianesi E, Ratziu V, George J. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. *J Hepatol* 2020; **73:** 202-209 [PMID: 32278004 DOI: 10.1016/j.jhep.2020.03.039]

4 **Eslam M**, Sanyal AJ, George J; International Consensus Panel. MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. *Gastroenterology* 2020; **158**: 1999-2014.e1 [PMID: 32044314 DOI: 10.1053/j.gastro.2019.11.312]

5 **Pang Q**, Zhang JY, Song SD, Qu K, Xu XS, Liu SS, Liu C. Central obesity and nonalcoholic fatty liver disease risk after adjusting for body mass index. *World J Gastroenterol* 2015; **21**: 1650-1662 [PMID: 25663786 DOI: 10.3748/wjg.v21.i5.1650]

6 **Younossi Z**, Tacke F, Arrese M, Chander Sharma B, Mostafa I, Bugianesi E, Wai-Sun Wong V, Yilmaz Y, George J, Fan J, Vos MB. Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. *Hepatology* 2019; **69**: 2672-2682 [PMID: 30179269 DOI: 10.1002/hep.30251]

7 **Mathurin P**, Lucey MR. Liver transplantation in patients with alcohol-related liver disease: current status and future directions. *Lancet Gastroenterol Hepatol* 2020; **5**: 507-514 [PMID: 32277903 DOI: 10.1016/S2468-1253(19)30451-0]

8 **Pais R**, Barritt AS 4th, Calmus Y, Scatton O, Runge T, Lebray P, Poynard T, Ratziu V, Conti F. NAFLD and liver transplantation: Current burden and expected challenges. *J Hepatol* 2016; **65**: 1245-1257 [PMID: 27486010 DOI: 10.1016/j.jhep.2016.07.033]

9 **Burra P**, Becchetti C, Germani G. NAFLD and liver transplantation: Disease burden, current management and future challenges. *JHEP Rep* 2020; **2**: 100192 [PMID: 33163950 DOI: 10.1016/j.jhepr.2020.100192]

10 **Wong RJ**, Aguilar M, Cheung R, Perumpail RB, Harrison SA, Younossi ZM, Ahmed A. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. *Gastroenterology* 2015; **148**: 547-555 [PMID: 25461851 DOI: 10.1053/j.gastro.2014.11.039]

11 **Younossi Z**, Stepanova M, Ong JP, Jacobson IM, Bugianesi E, Duseja A, Eguchi Y, Wong VW, Negro F, Yilmaz Y, Romero-Gomez M, George J, Ahmed A, Wong R, Younossi I, Ziayee M, Afendy A; Global Nonalcoholic Steatohepatitis Council. Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates. *Clin Gastroenterol Hepatol* 2019; **17**: 748-755.e3 [PMID: 29908364 DOI: 10.1016/j.cgh.2018.05.057]

12 **Rinella ME**. Nonalcoholic fatty liver disease: a systematic review. *JAMA* 2015; **313**: 2263-2273 [PMID: 26057287 DOI: 10.1001/jama.2015.5370]

13 **Marchesini G**, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, McCullough AJ, Natale S, Forlani G, Melchionda N. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. *Diabetes* 2001; **50**: 1844-1850 [PMID: 11473047 DOI: 10.2337/diabetes.50.8.1844]

14 **Tilg H**, Effenberger M. From NAFLD to MAFLD: when pathophysiology succeeds. *Nat Rev Gastroenterol Hepatol* 2020; **17**: 387-388 [PMID: 32461575 DOI: 10.1038/s41575-020-0316-6]

15 **European Association for the Study of the Liver (EASL).;** European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. *J Hepatol* 2016; **64:** 1388-1402 [PMID: 27062661 DOI: 10.1016/j.jhep.2015.11.004]

16 **Papatheodoridi M**, Cholongitas E. Diagnosis of Non-alcoholic Fatty Liver Disease (NAFLD): Current Concepts. *Curr Pharm Des* 2018; **24**: 4574-4586 [PMID: 30652642 DOI: 10.2174/1381612825666190117102111]

17 **Ludwig J**, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. *Mayo Clin Proc* 1980; **55**: 434-438 [PMID: 7382552]

18 **Fleming KA**, Morton JA, Barbatis C, Burns J, Canning S, McGee JO. Mallory bodies in alcoholic and non-alcoholic liver disease contain a common antigenic determinant. *Gut* 1981; **22**: 341-344 [PMID: 6166516 DOI: 10.1136/gut.22.5.341]

19 **Kleiner DE**, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A, Yeh M, McCullough AJ, Sanyal AJ; Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. *Hepatology* 2005; **41**: 1313-1321 [PMID: 15915461 DOI: 10.1002/hep.20701]

20 **Paternostro R**, Reiberger T, Bucsics T. Elastography-based screening for esophageal varices in patients with advanced chronic liver disease. *World J Gastroenterol* 2019; **25**: 308-329 [PMID: 30686900 DOI: 10.3748/wjg.v25.i3.308]

21 **Vilar-Gomez E**, Chalasani N. Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers. *J Hepatol* 2018; **68**: 305-315 [PMID: 29154965 DOI: 10.1016/j.jhep.2017.11.013]

22 **Kechagias S**, Ernersson A, Dahlqvist O, Lundberg P, Lindström T, Nystrom FH; Fast Food Study Group. Fast-food-based hyper-alimentation can induce rapid and profound elevation of serum alanine aminotransferase in healthy subjects. *Gut* 2008; **57**: 649-654 [PMID: 18276725 DOI: 10.1136/gut.2007.131797]

23 **Bergheim I**, Weber S, Vos M, Krämer S, Volynets V, Kaserouni S, McClain CJ, Bischoff SC. Antibiotics protect against fructose-induced hepatic lipid accumulation in mice: role of endotoxin. *J Hepatol* 2008; **48**: 983-992 [PMID: 18395289 DOI: 10.1016/j.jhep.2008.01.035]

24 **Moore JB**, Gunn PJ, Fielding BA. The role of dietary sugars and de novo lipogenesis in non-alcoholic fatty liver disease. *Nutrients* 2014; **6**: 5679-5703 [PMID: 25514388 DOI: 10.3390/nu6125679]

25 **Bugianesi E**, Moscatiello S, Ciaravella MF, Marchesini G. Insulin resistance in nonalcoholic fatty liver disease. *Curr Pharm Des* 2010; **16**: 1941-1951 [PMID: 20370677 DOI: 10.2174/138161210791208875]

26 **Guilherme A**, Virbasius JV, Puri V, Czech MP. Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. *Nat Rev Mol Cell Biol* 2008; **9**: 367-377 [PMID: 18401346 DOI: 10.1038/nrm2391]

27 **Kucukoglu O**, Sowa JP, Mazzolini GD, Syn WK, Canbay A. Hepatokines and adipokines in NASH-related hepatocellular carcinoma. *J Hepatol* 2021; **74**: 442-457 [PMID: 33161047 DOI: 10.1016/j.jhep.2020.10.030]

28 **Kolodziejczyk AA**, Zheng D, Shibolet O, Elinav E. The role of the microbiome in NAFLD and NASH. *EMBO Mol Med* 2019; **11** [PMID: 30591521 DOI: 10.15252/emmm.201809302]

29 **Safari Z**, Gérard P. The links between the gut microbiome and non-alcoholic fatty liver disease (NAFLD). *Cell Mol Life Sci* 2019; **76**: 1541-1558 [PMID: 30683985 DOI: 10.1007/s00018-019-03011-w]

30 **Eslam M**, Valenti L, Romeo S. Genetics and epigenetics of NAFLD and NASH: Clinical impact. *J Hepatol* 2018; **68**: 268-279 [PMID: 29122391 DOI: 10.1016/j.jhep.2017.09.003]

31 **Carlsson B**, Lindén D, Brolén G, Liljeblad M, Bjursell M, Romeo S, Loomba R. Review article: the emerging role of genetics in precision medicine for patients with non-alcoholic steatohepatitis. *Aliment Pharmacol Ther* 2020; **51**: 1305-1320 [PMID: 32383295 DOI: 10.1111/apt.15738]

32 **Targher G**, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. *N Engl J Med* 2010; **363**: 1341-1350 [PMID: 20879883 DOI: 10.1056/NEJMra0912063]

33 **Targher G**, Byrne CD, Lonardo A, Zoppini G, Barbui C. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis. *J Hepatol* 2016; **65**: 589-600 [PMID: 27212244 DOI: 10.1016/j.jhep.2016.05.013]

34 **Yamada T**, Fukatsu M, Suzuki S, Wada T, Yoshida T, Joh T. Fatty liver predicts impaired fasting glucose and type 2 diabetes mellitus in Japanese undergoing a health checkup. *J Gastroenterol Hepatol* 2010; **25**: 352-356 [PMID: 19817963 DOI: 10.1111/j.1440-1746.2009.05998.x]

35 **Fan JG**, Li F, Cai XB, Peng YD, Ao QH, Gao Y. Effects of nonalcoholic fatty liver disease on the development of metabolic disorders. *J Gastroenterol Hepatol* 2007; **22**: 1086-1091 [PMID: 17608855 DOI: 10.1111/j.1440-1746.2006.04781.x]

36 **Adams LA,** Waters OR, Knuiman MW, Elliott RR, Olynyk JK. NAFLD as a risk factor for the development of diabetes and the metabolic syndrome: an eleven-year follow-up study. *Am J Gastroenterol* 2009; **104:** 861-867 [PMID: 19293782 DOI: 10.1038/ajg.2009.67]

37 **Mantovani A**, Petracca G, Beatrice G, Csermely A, Lonardo A, Schattenberg JM, Tilg H, Byrne CD, Targher G. Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis. *Gut* 2020 [PMID: 33303564 DOI: 10.1136/gutjnl-2020-323082]

38 **Younossi ZM**, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. *Hepatology* 2016; **64**: 73-84 [PMID: 26707365 DOI: 10.1002/hep.28431]

39 **Dulai PS**, Singh S, Patel J, Soni M, Prokop LJ, Younossi Z, Sebastiani G, Ekstedt M, Hagstrom H, Nasr P, Stal P, Wong VW, Kechagias S, Hultcrantz R, Loomba R. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis. *Hepatology* 2017; **65**: 1557-1565 [PMID: 28130788 DOI: 10.1002/hep.29085]

40 **Hagström H,** Nasr P, Ekstedt M, Hammar U, Stål P, Hultcrantz R, Kechagias S. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. *J Hepatol* 2017; **67:** 1265-1273 [PMID: 28803953 DOI: 10.1016/j.jhep.2017.07.027]

41 **Mann JP**, Carter P, Armstrong MJ, Abdelaziz HK, Uppal H, Patel B, Chandran S, More R, Newsome PN, Potluri R. Hospital admission with non-alcoholic fatty liver disease is associated with increased all-cause mortality independent of cardiovascular risk factors. *PLoS One* 2020; **15**: e0241357 [PMID: 33108366 DOI: 10.1371/journal.pone.0241357]

42 **Stavropoulos K**, Imprialos K, Pittaras A, Faselis C, Narayan P, Kokkinos P. Lifestyle Modifications in Non-Alcoholic Fatty Liver Disease and Non- Alcoholic Steatohepatitis. *Curr Vasc Pharmacol* 2018; **16**: 239-245 [PMID: 28637408 DOI: 10.2174/1570161115666170621080835]

43 **Drew L.** Drug development: Sprint finish. *Nature* 2017; **551:** S86-S89 [PMID: 32080575 DOI: 10.1038/d41586-017-06926-1]

44 **Eslam M**, Alvani R, Shiha G. Obeticholic acid: towards first approval for NASH. *Lancet* 2019; **394**: 2131-2133 [PMID: 31813639 DOI: 10.1016/S0140-6736(19)32963-0]

45 **Jalili R**, Somi MH, Hosseinifard H, Salehnia F, Ghojazadeh M, Makhdami N, Shirmohammadi M. The Evaluation of Effective Drugs for the Treatment of Non-Alcoholic Fatty Liver Disease: A Systematic Review and Network Meta-Analysis. *Adv Pharm Bull* 2020; **10**: 542-555 [PMID: 33072533 DOI: 10.34172/apb.2020.065]

46 **Younossi ZM**, Ratziu V, Loomba R, Rinella M, Anstee QM, Goodman Z, Bedossa P, Geier A, Beckebaum S, Newsome PN, Sheridan D, Sheikh MY, Trotter J, Knapple W, Lawitz E, Abdelmalek MF, Kowdley KV, Montano-Loza AJ, Boursier J, Mathurin P, Bugianesi E, Mazzella G, Olveira A, Cortez-Pinto H, Graupera I, Orr D, Gluud LL, Dufour JF, Shapiro D, Campagna J, Zaru L, MacConell L, Shringarpure R, Harrison S, Sanyal AJ; REGENERATE Study Investigators. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. *Lancet* 2019; **394**: 2184-2196 [PMID: 31813633 DOI: 10.1016/S0140-6736(19)33041-7]

47 **Moctezuma-Velazquez C**, Márquez-Guillén E, Torre A. Obesity in the Liver Transplant Setting. *Nutrients* 2019; **11** [PMID: 31652761 DOI: 10.3390/nu11112552]

48 **Berzigotti A**, Garcia-Tsao G, Bosch J, Grace ND, Burroughs AK, Morillas R, Escorsell A, Garcia-Pagan JC, Patch D, Matloff DS, Groszmann RJ; Portal Hypertension Collaborative Group. Obesity is an independent risk factor for clinical decompensation in patients with cirrhosis. *Hepatology* 2011; **54**: 555-561 [PMID: 21567436 DOI: 10.1002/hep.24418]

49 **Schlansky B**, Naugler WE, Orloff SL, Enestvedt CK. Higher Mortality and Survival Benefit in Obese Patients Awaiting Liver Transplantation. *Transplantation* 2016; **100**: 2648-2655 [PMID: 27575690 DOI: 10.1097/TP.0000000000001461]

50 **Uusitupa M**. Lifestyle changes and cardiovascular risk reduction in diabetes. *Lancet Diabetes Endocrinol* 2016; **4**: 877-878 [PMID: 27595919 DOI: 10.1016/S2213-8587(16)30185-1]

51 **Peng L,** Wang J, Li F. Weight reduction for non-alcoholic fatty liver disease. *Cochrane Database Syst Rev* 2011; **6:** CD003619 [PMID: 21678341 DOI: 10.1002/14651858.CD003619.pub3]

52 **Lazo M**, Solga SF, Horska A, Bonekamp S, Diehl AM, Brancati FL, Wagenknecht LE, Pi-Sunyer FX, Kahn SE, Clark JM; Fatty Liver Subgroup of the Look AHEAD Research Group. Effect of a 12-month intensive lifestyle intervention on hepatic steatosis in adults with type 2 diabetes. *Diabetes Care* 2010; **33**: 2156-2163 [PMID: 20664019 DOI: 10.2337/dc10-0856]

53 **Suzuki A**, Lindor K, St Saver J, Lymp J, Mendes F, Muto A, Okada T, Angulo P. Effect of changes on body weight and lifestyle in nonalcoholic fatty liver disease. *J Hepatol* 2005; **43**: 1060-1066 [PMID: 16140415 DOI: 10.1016/j.jhep.2005.06.008]

54 **Jensen MD,** Ryan DH, Apovian CM, Ard JD, Comuzzie AG, Donato KA, Hu FB, Hubbard VS, Jakicic JM, Kushner RF, Loria CM, Millen BE, Nonas CA, Pi-Sunyer FX, Stevens J, Stevens VJ, Wadden TA, Wolfe BM, Yanovski SZ; American College of Cardiology/American Heart Association Task Force on Practice Guidelines; Obesity Society. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. *J Am Coll Cardiol* 2014; **63:** 2985-3023 [PMID: 24239920 DOI: 10.1016/j.jacc.2013.11.004]

55 **Wong VW**, Wong GL, Chan RS, Shu SS, Cheung BH, Li LS, Chim AM, Chan CK, Leung JK, Chu WC, Woo J, Chan HL. Beneficial effects of lifestyle intervention in non-obese patients with non-alcoholic fatty liver disease. *J Hepatol* 2018; **69**: 1349-1356 [PMID: 30142427 DOI: 10.1016/j.jhep.2018.08.011]

56 **Unger LW**, Forstner B, Muckenhuber M, Scheuba K, Eigenbauer E, Scheiner B, Pfisterer N, Paternostro R, Trauner M, Mandorfer M, Reiberger T. Hepatic Steatosis in Lean Patients: Risk Factors and Impact on Mortality. *Dig Dis Sci* 2020; **65**: 2712-2718 [PMID: 31875288 DOI: 10.1007/s10620-019-06000-y]

57 **Berzigotti A**, Albillos A, Villanueva C, Genescá J, Ardevol A, Augustín S, Calleja JL, Bañares R, García-Pagán JC, Mesonero F, Bosch J; Ciberehd SportDiet Collaborative Group. Effects of an intensive lifestyle intervention program on portal hypertension in patients with cirrhosis and obesity: The SportDiet study. *Hepatology* 2017; **65**: 1293-1305 [PMID: 27997989 DOI: 10.1002/hep.28992]

58 **Romero-Gómez M**, Zelber-Sagi S, Trenell M. Treatment of NAFLD with diet, physical activity and exercise. *J Hepatol* 2017; **67**: 829-846 [PMID: 28545937 DOI: 10.1016/j.jhep.2017.05.016]

59 **Bandi JC**, García-Pagán JC, Escorsell A, François E, Moitinho E, Rodés J, Bosch J. Effects of propranolol on the hepatic hemodynamic response to physical exercise in patients with cirrhosis. *Hepatology* 1998; **28**: 677-682 [PMID: 9731558 DOI: 10.1002/hep.510280312]

60 **Albillos A**, Zamora J, Martínez J, Arroyo D, Ahmad I, De-la-Peña J, Garcia-Pagán JC, Lo GH, Sarin S, Sharma B, Abraldes JG, Bosch J, Garcia-Tsao G; Baveno Cooperation. Stratifying risk in the prevention of recurrent variceal hemorrhage: Results of an individual patient meta-analysis. *Hepatology* 2017; **66**: 1219-1231 [PMID: 28543862 DOI: 10.1002/hep.29267]

61 **Wilding JPH,** Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF; STEP 1 Study Group. Once-Weekly Semaglutide in Adults with Overweight or Obesity. *N Engl J Med* 2021; **384:** 989 [PMID: 33567185 DOI: 10.1056/NEJMoa2032183]

62 **Benjamin EJ**, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, de Ferranti SD, Floyd J, Fornage M, Gillespie C, Isasi CR, Jiménez MC, Jordan LC, Judd SE, Lackland D, Lichtman JH, Lisabeth L, Liu S, Longenecker CT, Mackey RH, Matsushita K, Mozaffarian D, Mussolino ME, Nasir K, Neumar RW, Palaniappan L, Pandey DK, Thiagarajan RR, Reeves MJ, Ritchey M, Rodriguez CJ, Roth GA, Rosamond WD, Sasson C, Towfighi A, Tsao CW, Turner MB, Virani SS, Voeks JH, Willey JZ, Wilkins JT, Wu JH, Alger HM, Wong SS, Muntner P; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association. *Circulation* 2017; **135**: e146-e603 [PMID: 28122885 DOI: 10.1161/CIR.0000000000000485]

63 **Unger LW**, Forstner B, Schneglberger S, Muckenhuber M, Eigenbauer E, Scheiner B, Mandorfer M, Trauner M, Reiberger T. Patterns and prevalence of dyslipidemia in patients with different etiologies of chronic liver disease. *Wien Klin Wochenschr* 2019; **131**: 395-403 [PMID: 31493100 DOI: 10.1007/s00508-019-01544-5]

64 **Cholesterol Treatment Trialists’ (CTT) Collaboration**, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. *Lancet* 2010; **376**: 1670-1681 [PMID: 21067804 DOI: 10.1016/S0140-6736(10)61350-5]

65 **Abd TT**, Jacobson TA. Statin-induced myopathy: a review and update. *Expert Opin Drug Saf* 2011; **10**: 373-387 [PMID: 21342078 DOI: 10.1517/14740338.2011.540568]

66 **Blais P**, Lin M, Kramer JR, El-Serag HB, Kanwal F. Statins Are Underutilized in Patients with Nonalcoholic Fatty Liver Disease and Dyslipidemia. *Dig Dis Sci* 2016; **61**: 1714-1720 [PMID: 26707137 DOI: 10.1007/s10620-015-4000-6]

67 **Wong JC**, Chan HL, Tse YK, Yip TC, Wong VW, Wong GL. Statins reduce the risk of liver decompensation and death in chronic viral hepatitis: a propensity score weighted landmark analysis. *Aliment Pharmacol Ther* 2017; **46**: 1001-1010 [PMID: 28940673 DOI: 10.1111/apt.14341]

68 **Kim RG**, Loomba R, Prokop LJ, Singh S. Statin Use and Risk of Cirrhosis and Related Complications in Patients With Chronic Liver Diseases: A Systematic Review and Meta-analysis. *Clin Gastroenterol Hepatol* 2017; **15**: 1521-1530.e8 [PMID: 28479502 DOI: 10.1016/j.cgh.2017.04.039]

69 **Abraldes JG**, Albillos A, Bañares R, Turnes J, González R, García-Pagán JC, Bosch J. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial. *Gastroenterology* 2009; **136**: 1651-1658 [PMID: 19208350 DOI: 10.1053/j.gastro.2009.01.043]

70 **La Mura V**, Pasarín M, Meireles CZ, Miquel R, Rodríguez-Vilarrupla A, Hide D, Gracia-Sancho J, García-Pagán JC, Bosch J, Abraldes JG. Effects of simvastatin administration on rodents with lipopolysaccharide-induced liver microvascular dysfunction. *Hepatology* 2013; **57**: 1172-1181 [PMID: 23184571 DOI: 10.1002/hep.26127]

71 **Marrone G**, Russo L, Rosado E, Hide D, García-Cardeña G, García-Pagán JC, Bosch J, Gracia-Sancho J. The transcription factor KLF2 mediates hepatic endothelial protection and paracrine endothelial-stellate cell deactivation induced by statins. *J Hepatol* 2013; **58**: 98-103 [PMID: 22989565 DOI: 10.1016/j.jhep.2012.08.026]

72 **Nelson A**, Torres DM, Morgan AE, Fincke C, Harrison SA. A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: A randomized placebo-controlled trial. *J Clin Gastroenterol* 2009; **43**: 990-994 [PMID: 19448566 DOI: 10.1097/MCG.0b013e31819c392e]

73 **Yang YH**, Chen WC, Tsan YT, Chen MJ, Shih WT, Tsai YH, Chen PC. Statin use and the risk of cirrhosis development in patients with hepatitis C virus infection. *J Hepatol* 2015; **63**: 1111-1117 [PMID: 26196278 DOI: 10.1016/j.jhep.2015.07.006]

74 **Mohanty A**, Tate JP, Garcia-Tsao G. Statins Are Associated With a Decreased Risk of Decompensation and Death in Veterans With Hepatitis C-Related Compensated Cirrhosis. *Gastroenterology* 2016; **150**: 430-40.e1 [PMID: 26484707 DOI: 10.1053/j.gastro.2015.10.007]

75 **Tsan YT**, Lee CH, Ho WC, Lin MH, Wang JD, Chen PC. Statins and the risk of hepatocellular carcinoma in patients with hepatitis C virus infection. *J Clin Oncol* 2013; **31**: 1514-1521 [PMID: 23509319 DOI: 10.1200/JCO.2012.44.6831]

76 **Simon TG**, Bonilla H, Yan P, Chung RT, Butt AA. Atorvastatin and fluvastatin are associated with dose-dependent reductions in cirrhosis and hepatocellular carcinoma, among patients with hepatitis C virus: Results from ERCHIVES. *Hepatology* 2016; **64**: 47-57 [PMID: 26891205 DOI: 10.1002/hep.28506]

77 **Huang YW**, Lee CL, Yang SS, Fu SC, Chen YY, Wang TC, Hu JT, Chen DS. Statins Reduce the Risk of Cirrhosis and Its Decompensation in Chronic Hepatitis B Patients: A Nationwide Cohort Study. *Am J Gastroenterol* 2016; **111**: 976-985 [PMID: 27166128 DOI: 10.1038/ajg.2016.179]

78 **Stojakovic T**, Claudel T, Putz-Bankuti C, Fauler G, Scharnagl H, Wagner M, Sourij H, Stauber RE, Winkler K, März W, Wascher TC, Trauner M. Low-dose atorvastatin improves dyslipidemia and vascular function in patients with primary biliary cirrhosis after one year of treatment. *Atherosclerosis* 2010; **209**: 178-183 [PMID: 19782361 DOI: 10.1016/j.atherosclerosis.2009.08.052]

79 **Cash WJ**, O'Neill S, O'Donnell ME, McCance DR, Young IS, McEneny J, McDougall NI, Callender ME. Randomized controlled trial assessing the effect of simvastatin in primary biliary cirrhosis. *Liver Int* 2013; **33**: 1166-1174 [PMID: 23672463 DOI: 10.1111/liv.12191]

80 **Marchesini G**, Brizi M, Morselli-Labate AM, Bianchi G, Bugianesi E, McCullough AJ, Forlani G, Melchionda N. Association of nonalcoholic fatty liver disease with insulin resistance. *Am J Med* 1999; **107**: 450-455 [PMID: 10569299 DOI: 10.1016/s0002-9343(99)00271-5]

81 **Williamson RM**, Price JF, Glancy S, Perry E, Nee LD, Hayes PC, Frier BM, Van Look LA, Johnston GI, Reynolds RM, Strachan MW; Edinburgh Type 2 Diabetes Study Investigators. Prevalence of and risk factors for hepatic steatosis and nonalcoholic Fatty liver disease in people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study. *Diabetes Care* 2011; **34**: 1139-1144 [PMID: 21478462 DOI: 10.2337/dc10-2229]

82 **Portillo-Sanchez P,** Bril F, Maximos M, Lomonaco R, Biernacki D, Orsak B, Subbarayan S, Webb A, Hecht J, Cusi K. High Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus and Normal Plasma Aminotransferase Levels. *J Clin Endocrinol Metab* 2015; **100:** 2231-2238 [PMID: 25885947 DOI: 10.1210/jc.2015-1966]

83 **Fracanzani AL**, Valenti L, Bugianesi E, Andreoletti M, Colli A, Vanni E, Bertelli C, Fatta E, Bignamini D, Marchesini G, Fargion S. Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. *Hepatology* 2008; **48**: 792-798 [PMID: 18752331 DOI: 10.1002/hep.22429]

84 **Abrams GA**, Kunde SS, Lazenby AJ, Clements RH. Portal fibrosis and hepatic steatosis in morbidly obese subjects: A spectrum of nonalcoholic fatty liver disease. *Hepatology* 2004; **40**: 475-483 [PMID: 15368453 DOI: 10.1002/hep.20323]

85 **Goh GB**, Pagadala MR, Dasarathy J, Unalp-Arida A, Sargent R, Hawkins C, Sourianarayanane A, Khiyami A, Yerian L, Pai RK, Dasarathy S, McCullough AJ. Clinical spectrum of non-alcoholic fatty liver disease in diabetic and non-diabetic patients. *BBA Clin* 2015; **3**: 141-145 [PMID: 26675585 DOI: 10.1016/j.bbacli.2014.09.001]

86 **Bazick J**, Donithan M, Neuschwander-Tetri BA, Kleiner D, Brunt EM, Wilson L, Doo E, Lavine J, Tonascia J, Loomba R. Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD. *Diabetes Care* 2015; **38**: 1347-1355 [PMID: 25887357 DOI: 10.2337/dc14-1239]

87 **Hossain N**, Afendy A, Stepanova M, Nader F, Srishord M, Rafiq N, Goodman Z, Younossi Z. Independent predictors of fibrosis in patients with nonalcoholic fatty liver disease. *Clin Gastroenterol Hepatol* 2009; **7**: 1224-1229, 1229.e1-1229.e2 [PMID: 19559819 DOI: 10.1016/j.cgh.2009.06.007]

88 **Doycheva I**, Cui J, Nguyen P, Costa EA, Hooker J, Hofflich H, Bettencourt R, Brouha S, Sirlin CB, Loomba R. Non-invasive screening of diabetics in primary care for NAFLD and advanced fibrosis by MRI and MRE. *Aliment Pharmacol Ther* 2016; **43**: 83-95 [PMID: 26369383 DOI: 10.1111/apt.13405]

89 **Williams CD**, Stengel J, Asike MI, Torres DM, Shaw J, Contreras M, Landt CL, Harrison SA. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. *Gastroenterology* 2011; **140**: 124-131 [PMID: 20858492 DOI: 10.1053/j.gastro.2010.09.038]

90 **Loomba R**, Abraham M, Unalp A, Wilson L, Lavine J, Doo E, Bass NM; Nonalcoholic Steatohepatitis Clinical Research Network. Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis. *Hepatology* 2012; **56**: 943-951 [PMID: 22505194 DOI: 10.1002/hep.25772]

91 **Kwok R**, Choi KC, Wong GL, Zhang Y, Chan HL, Luk AO, Shu SS, Chan AW, Yeung MW, Chan JC, Kong AP, Wong VW. Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study. *Gut* 2016; **65**: 1359-1368 [PMID: 25873639 DOI: 10.1136/gutjnl-2015-309265]

92 **Koehler EM**, Plompen EP, Schouten JN, Hansen BE, Darwish Murad S, Taimr P, Leebeek FW, Hofman A, Stricker BH, Castera L, Janssen HL. Presence of diabetes mellitus and steatosis is associated with liver stiffness in a general population: The Rotterdam study. *Hepatology* 2016; **63**: 138-147 [PMID: 26171685 DOI: 10.1002/hep.27981]

93 **Tilg H**, Moschen AR, Roden M. NAFLD and diabetes mellitus. *Nat Rev Gastroenterol Hepatol* 2017; **14**: 32-42 [PMID: 27729660 DOI: 10.1038/nrgastro.2016.147]

94 **Angulo P**, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, Charatcharoenwitthaya P, Mills PR, Keach JC, Lafferty HD, Stahler A, Haflidadottir S, Bendtsen F. Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. *Gastroenterology* 2015; **149**: 389-97.e10 [PMID: 25935633 DOI: 10.1053/j.gastro.2015.04.043]

95 **Hazlehurst JM**, Woods C, Marjot T, Cobbold JF, Tomlinson JW. Non-alcoholic fatty liver disease and diabetes. *Metabolism* 2016; **65**: 1096-1108 [PMID: 26856933 DOI: 10.1016/j.metabol.2016.01.001]

96 **de Marco R**, Locatelli F, Zoppini G, Verlato G, Bonora E, Muggeo M. Cause-specific mortality in type 2 diabetes. The Verona Diabetes Study. *Diabetes Care* 1999; **22**: 756-761 [PMID: 10332677 DOI: 10.2337/diacare.22.5.756]

97 **Younossi ZM**, Gramlich T, Matteoni CA, Boparai N, McCullough AJ. Nonalcoholic fatty liver disease in patients with type 2 diabetes. *Clin Gastroenterol Hepatol* 2004; **2**: 262-265 [PMID: 15017611 DOI: 10.1016/s1542-3565(04)00014-x]

98 **Phielix E**, Szendroedi J, Roden M. The role of metformin and thiazolidinediones in the regulation of hepatic glucose metabolism and its clinical impact. *Trends Pharmacol Sci* 2011; **32**: 607-616 [PMID: 21824668 DOI: 10.1016/j.tips.2011.06.006]

99 **Belfort R,** Harrison SA, Brown K, Darland C, Finch J, Hardies J, Balas B, Gastaldelli A, Tio F, Pulcini J, Berria R, Ma JZ, Dwivedi S, Havranek R, Fincke C, DeFronzo R, Bannayan GA, Schenker S, Cusi K. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. *N Engl J Med* 2006; **355:** 2297-2307 [PMID: 17135584 DOI: 10.1056/NEJMoa060326]

100 **Aithal GP**, Thomas JA, Kaye PV, Lawson A, Ryder SD, Spendlove I, Austin AS, Freeman JG, Morgan L, Webber J. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. *Gastroenterology* 2008; **135**: 1176-1184 [PMID: 18718471 DOI: 10.1053/j.gastro.2008.06.047]

101 **Sanyal AJ,** Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, Neuschwander-Tetri BA, Lavine JE, Tonascia J, Unalp A, Van Natta M, Clark J, Brunt EM, Kleiner DE, Hoofnagle JH, Robuck PR; NASH CRN. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. *N Engl J Med* 2010; **362:** 1675-1685 [PMID: 20427778 DOI: 10.1056/NEJMoa0907929]

102 **Cusi K,** Orsak B, Bril F, Lomonaco R, Hecht J, Ortiz-Lopez C, Tio F, Hardies J, Darland C, Musi N, Webb A, Portillo-Sanchez P. Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial. *Ann Intern Med* 2016; **165:** 305-315 [PMID: 27322798 DOI: 10.7326/M15-1774]

103 **Fruci B**, Giuliano S, Mazza A, Malaguarnera R, Belfiore A. Nonalcoholic Fatty liver: a possible new target for type 2 diabetes prevention and treatment. *Int J Mol Sci* 2013; **14**: 22933-22966 [PMID: 24264040 DOI: 10.3390/ijms141122933]

104 **Armstrong MJ**, Gaunt P, Aithal GP, Barton D, Hull D, Parker R, Hazlehurst JM, Guo K; LEAN trial team, Abouda G, Aldersley MA, Stocken D, Gough SC, Tomlinson JW, Brown RM, Hübscher SG, Newsome PN. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. *Lancet* 2016; **387**: 679-690 [PMID: 26608256 DOI: 10.1016/S0140-6736(15)00803-X]

105 **Bugianesi E**, Gentilcore E, Manini R, Natale S, Vanni E, Villanova N, David E, Rizzetto M, Marchesini G. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. *Am J Gastroenterol* 2005; **100**: 1082-1090 [PMID: 15842582 DOI: 10.1111/j.1572-0241.2005.41583.x]

106 **Haukeland JW**, Konopski Z, Eggesbø HB, von Volkmann HL, Raschpichler G, Bjøro K, Haaland T, Løberg EM, Birkeland K. Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial. *Scand J Gastroenterol* 2009; **44**: 853-860 [PMID: 19811343 DOI: 10.1080/00365520902845268]

107 **Shields WW**, Thompson KE, Grice GA, Harrison SA, Coyle WJ. The Effect of Metformin and Standard Therapy versus Standard Therapy alone in Nondiabetic Patients with Insulin Resistance and Nonalcoholic Steatohepatitis (NASH): A Pilot Trial. *Therap Adv Gastroenterol* 2009; **2**: 157-163 [PMID: 21180541 DOI: 10.1177/1756283X09105462]

108 **Lavine JE**, Schwimmer JB, Van Natta ML, Molleston JP, Murray KF, Rosenthal P, Abrams SH, Scheimann AO, Sanyal AJ, Chalasani N, Tonascia J, Ünalp A, Clark JM, Brunt EM, Kleiner DE, Hoofnagle JH, Robuck PR; Nonalcoholic Steatohepatitis Clinical Research Network. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. *JAMA* 2011; **305**: 1659-1668 [PMID: 21521847 DOI: 10.1001/jama.2011.520]

109 **Torres DM**, Jones FJ, Shaw JC, Williams CD, Ward JA, Harrison SA. Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: a 12-month randomized, prospective, open- label trial. *Hepatology* 2011; **54**: 1631-1639 [PMID: 21748770 DOI: 10.1002/hep.24558]

110 **Sjöström L**, Lindroos AK, Peltonen M, Torgerson J, Bouchard C, Carlsson B, Dahlgren S, Larsson B, Narbro K, Sjöström CD, Sullivan M, Wedel H; Swedish Obese Subjects Study Scientific Group. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. *N Engl J Med* 2004; **351**: 2683-2693 [PMID: 15616203 DOI: 10.1056/NEJMoa035622]

111 **Sjöström L**, Narbro K, Sjöström CD, Karason K, Larsson B, Wedel H, Lystig T, Sullivan M, Bouchard C, Carlsson B, Bengtsson C, Dahlgren S, Gummesson A, Jacobson P, Karlsson J, Lindroos AK, Lönroth H, Näslund I, Olbers T, Stenlöf K, Torgerson J, Agren G, Carlsson LM; Swedish Obese Subjects Study. Effects of bariatric surgery on mortality in Swedish obese subjects. *N Engl J Med* 2007; **357**: 741-752 [PMID: 17715408 DOI: 10.1056/NEJMoa066254]

112 **Carlsson LMS**, Sjöholm K, Jacobson P, Andersson-Assarsson JC, Svensson PA, Taube M, Carlsson B, Peltonen M. Life Expectancy after Bariatric Surgery in the Swedish Obese Subjects Study. *N Engl J Med* 2020; **383**: 1535-1543 [PMID: 33053284 DOI: 10.1056/NEJMoa2002449]

113 **Yoshino M**, Kayser BD, Yoshino J, Stein RI, Reeds D, Eagon JC, Eckhouse SR, Watrous JD, Jain M, Knight R, Schechtman K, Patterson BW, Klein S. Effects of Diet versus Gastric Bypass on Metabolic Function in Diabetes. *N Engl J Med* 2020; **383**: 721-732 [PMID: 32813948 DOI: 10.1056/NEJMoa2003697]

114 **Lassailly G**, Caiazzo R, Buob D, Pigeyre M, Verkindt H, Labreuche J, Raverdy V, Leteurtre E, Dharancy S, Louvet A, Romon M, Duhamel A, Pattou F, Mathurin P. Bariatric Surgery Reduces Features of Nonalcoholic Steatohepatitis in Morbidly Obese Patients. *Gastroenterology* 2015; **149**: 379-88; quiz e15-6 [PMID: 25917783 DOI: 10.1053/j.gastro.2015.04.014]

115 **Adams TD**, Davidson LE, Litwin SE, Kim J, Kolotkin RL, Nanjee MN, Gutierrez JM, Frogley SJ, Ibele AR, Brinton EA, Hopkins PN, McKinlay R, Simper SC, Hunt SC. Weight and Metabolic Outcomes 12 Years after Gastric Bypass. *N Engl J Med* 2017; **377**: 1143-1155 [PMID: 28930514 DOI: 10.1056/NEJMoa1700459]

116 **Panunzi S,** Maltese S, Verrastro O, Labbate L, De Gaetano A, Pompili M, Capristo E, Bornstein SR, Mingrone G. Pioglitazone and bariatric surgery are the most effective treatments for non-alcoholic steatohepatitis: A hierarchical network meta-analysis. *Diabetes Obes Metab* 2021; **23:** 980-990 [PMID: 33368954 DOI:10.1111/dom.14304]

117 **Goossens N**, Hoshida Y, Song WM, Jung M, Morel P, Nakagawa S, Zhang B, Frossard JL, Spahr L, Friedman SL, Negro F, Rubbia-Brandt L, Giostra E. Nonalcoholic Steatohepatitis Is Associated With Increased Mortality in Obese Patients Undergoing Bariatric Surgery. *Clin Gastroenterol Hepatol* 2016; **14**: 1619-1628 [PMID: 26492845 DOI: 10.1016/j.cgh.2015.10.010]

118 **Eilenberg M**, Langer FB, Beer A, Trauner M, Prager G, Staufer K. Significant Liver-Related Morbidity After Bariatric Surgery and Its Reversal-a Case Series. *Obes Surg* 2018; **28**: 812-819 [PMID: 28965313 DOI: 10.1007/s11695-017-2925-x]

119 **Reiberger T**, Püspök A, Schoder M, Baumann-Durchschein F, Bucsics T, Datz C, Dolak W, Ferlitsch A, Finkenstedt A, Graziadei I, Hametner S, Karnel F, Krones E, Maieron A, Mandorfer M, Peck-Radosavljevic M, Rainer F, Schwabl P, Stadlbauer V, Stauber R, Tilg H, Trauner M, Zoller H, Schöfl R, Fickert P. Austrian consensus guidelines on the management and treatment of portal hypertension (Billroth III). *Wien Klin Wochenschr* 2017; **129**: 135-158 [PMID: 29063233 DOI: 10.1007/s00508-017-1262-3]

120 **Kwong A**, Kim WR, Lake JR, Smith JM, Schladt DP, Skeans MA, Noreen SM, Foutz J, Miller E, Snyder JJ, Israni AK, Kasiske BL. OPTN/SRTR 2018 Annual Data Report: Liver. *Am J Transplant* 2020; **20 Suppl s1**: 193-299 [PMID: 31898413 DOI: 10.1111/ajt.15674]

121 **European Association for the Study of the Liver.** EASL Clinical Practice Guidelines: Liver transplantation. *J Hepatol* 2016; **64**: 433-485 [PMID: 26597456 DOI: 10.1016/j.jhep.2015.10.006]

122 **Hakeem AR**, Cockbain AJ, Raza SS, Pollard SG, Toogood GJ, Attia MA, Ahmad N, Hidalgo EL, Prasad KR, Menon KV. Increased morbidity in overweight and obese liver transplant recipients: a single-center experience of 1325 patients from the United Kingdom. *Liver Transpl* 2013; **19**: 551-562 [PMID: 23408499 DOI: 10.1002/lt.23618]

123 **LaMattina JC**, Foley DP, Fernandez LA, Pirsch JD, Musat AI, D'Alessandro AM, Mezrich JD. Complications associated with liver transplantation in the obese recipient. *Clin Transplant* 2012; **26**: 910-918 [PMID: 22694047 DOI: 10.1111/j.1399-0012.2012.01669.x]

124 **Sawyer RG**, Pelletier SJ, Pruett TL. Increased early morbidity and mortality with acceptable long-term function in severely obese patients undergoing liver transplantation. *Clin Transplant* 1999; **13**: 126-130 [PMID: 10081649 DOI: 10.1034/j.1399-0012.1999.130111.x]

125 **Sundaram V**, Kaung A, Rajaram A, Lu SC, Tran TT, Nissen NN, Klein AS, Jalan R, Charlton MR, Jeon CY. Obesity is independently associated with infection in hospitalised patients with end-stage liver disease. *Aliment Pharmacol Ther* 2015; **42**: 1271-1280 [PMID: 26510540 DOI: 10.1111/apt.13426]

126 **Barone M**, Viggiani MT, Losurdo G, Principi M, Leandro G, Di Leo A. Systematic review with meta-analysis: post-operative complications and mortality risk in liver transplant candidates with obesity. *Aliment Pharmacol Ther* 2017; **46**: 236-245 [PMID: 28488418 DOI: 10.1111/apt.14139]

127 **Malik SM**, deVera ME, Fontes P, Shaikh O, Ahmad J. Outcome after liver transplantation for NASH cirrhosis. *Am J Transplant* 2009; **9**: 782-793 [PMID: 19344467 DOI: 10.1111/j.1600-6143.2009.02590.x]

128 **Unger LW,** Mandorfer M, Reiberger T. Portal Hypertension after Liver Transplantation—Causes and Management. *Curr Hepatol Rep* 2019; **18:** 59-66 [DOI: 10.1007/s11901-019-00450-8]

129 **Richards J**, Gunson B, Johnson J, Neuberger J. Weight gain and obesity after liver transplantation. *Transpl Int* 2005; **18**: 461-466 [PMID: 15773968 DOI: 10.1111/j.1432-2277.2004.00067.x]

130 **Choudhary NS**, Saigal S, Saraf N, Mohanka R, Rastogi A, Goja S, Menon PB, Mishra S, Mittal A, Soin AS. Sarcopenic obesity with metabolic syndrome: a newly recognized entity following living donor liver transplantation. *Clin Transplant* 2015; **29**: 211-215 [PMID: 25594826 DOI: 10.1111/ctr.12505]

131 **Hong HC**, Hwang SY, Choi HY, Yoo HJ, Seo JA, Kim SG, Kim NH, Baik SH, Choi DS, Choi KM. Relationship between sarcopenia and nonalcoholic fatty liver disease: the Korean Sarcopenic Obesity Study. *Hepatology* 2014; **59**: 1772-1778 [PMID: 23996808 DOI: 10.1002/hep.26716]

132 **Mathur S**, Janaudis-Ferreira T, Wickerson L, Singer LG, Patcai J, Rozenberg D, Blydt-Hansen T, Hartmann EL, Haykowsky M, Helm D, High K, Howes N, Kamath BM, Lands L, Marzolini S, Sonnenday C. Meeting report: consensus recommendations for a research agenda in exercise in solid organ transplantation. *Am J Transplant* 2014; **14**: 2235-2245 [PMID: 25135579 DOI: 10.1111/ajt.12874]

133 **Dunn MA**, Rogal SS, Duarte-Rojo A, Lai JC. Physical Function, Physical Activity, and Quality of Life After Liver Transplantation. *Liver Transpl* 2020; **26**: 702-708 [PMID: 32128971 DOI: 10.1002/lt.25742]

134 **Serper M**, Barankay I, Chadha S, Shults J, Jones LS, Olthoff KM, Reese PP. A randomized, controlled, behavioral intervention to promote walking after abdominal organ transplantation: results from the LIFT study. *Transpl Int* 2020; **33**: 632-643 [PMID: 31925833 DOI: 10.1111/tri.13570]

135 **Duarte-Rojo A**, Bloomer PM, Rogers RJ, Hassan MA, Dunn MA, Tevar AD, Vivis SL, Bataller R, Hughes CB, Ferrando AA, Jakicic JM, Kim WR. Introducing EL-FIT (Exercise and Liver FITness): A Smartphone App to Prehabilitate and Monitor Liver Transplant Candidates. *Liver Transpl* 2021; **27**: 502-512 [PMID: 33232547 DOI: 10.1002/lt.25950]

136 **Lopez-Lopez V,** Ruiz-Manzanera JJ, Eshmuminov D, Lehmann K, Schneider M, von der Groeben M, de Angulo DR, Gajownik U, Pons JA, Sanchez-Bueno F, Robles-Campos R, Ramirez-Romero P. Are We Ready for Bariatric Surgery in a Liver Transplant Program? A Meta-Analysis. *Obes Surg* 2020; **31:** 1214-1222 [PMID: 33225408 DOI: 10.1007/s11695-020-05118-7]

137 **Johnston SD**, Morris JK, Cramb R, Gunson BK, Neuberger J. Cardiovascular morbidity and mortality after orthotopic liver transplantation. *Transplantation* 2002; **73**: 901-906 [PMID: 11923689 DOI: 10.1097/00007890-200203270-00012]

138 **Unger LW**, Berlakovich GA, Trauner M, Reiberger T. Management of portal hypertension before and after liver transplantation. *Liver Transpl* 2018; **24**: 112-121 [PMID: 28752925 DOI: 10.1002/lt.24830]

139 **Patel SS**, Rodriguez VA, Siddiqui MB, Faridnia M, Lin FP, Chandrakumaran A, Laurenzano J, Clinton J, Kowlgi GN, Kirkman D, Sima AP, Liptrap E, Bhati C, Siddiqui MS. The Impact of Coronary Artery Disease and Statins on Survival After Liver Transplantation. *Liver Transpl* 2019; **25**: 1514-1523 [PMID: 31344758 DOI: 10.1002/lt.25613]

140 **Gracia-Sancho J**, García-Calderó H, Hide D, Marrone G, Guixé-Muntet S, Peralta C, García-Pagán JC, Abraldes JG, Bosch J. Simvastatin maintains function and viability of steatotic rat livers procured for transplantation. *J Hepatol* 2013; **58**: 1140-1146 [PMID: 23428876 DOI: 10.1016/j.jhep.2013.02.005]

141 **Russo L**, Gracia-Sancho J, García-Calderó H, Marrone G, García-Pagán JC, García-Cardeña G, Bosch J. Addition of simvastatin to cold storage solution prevents endothelial dysfunction in explanted rat livers. *Hepatology* 2012; **55**: 921-930 [PMID: 22031447 DOI: 10.1002/hep.24755]

142 **Bianchi G**, Marchesini G, Marzocchi R, Pinna AD, Zoli M. Metabolic syndrome in liver transplantation: relation to etiology and immunosuppression. *Liver Transpl* 2008; **14**: 1648-1654 [PMID: 18975273 DOI: 10.1002/lt.21588]

143 **Heisel O**, Heisel R, Balshaw R, Keown P. New onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta-analysis. *Am J Transplant* 2004; **4**: 583-595 [PMID: 15023151 DOI: 10.1046/j.1600-6143.2003.00372.x]

144 **Wallia A**, Parikh ND, O'Shea-Mahler E, Schmidt K, DeSantis AJ, Tian L, Levitsky J, Molitch ME. Glycemic control by a glucose management service and infection rates after liver transplantation. *Endocr Pract* 2011; **17**: 546-551 [PMID: 21324822 DOI: 10.4158/EP10343.OR]

145 **Park C**, Hsu C, Neelakanta G, Nourmand H, Braunfeld M, Wray C, Steadman RH, Hu KQ, Cheng RT, Xia VW. Severe intraoperative hyperglycemia is independently associated with surgical site infection after liver transplantation. *Transplantation* 2009; **87**: 1031-1036 [PMID: 19352123 DOI: 10.1097/TP.0b013e31819cc3e6]

146 **Wallia A**, Parikh ND, Molitch ME, Mahler E, Tian L, Huang JJ, Levitsky J. Posttransplant hyperglycemia is associated with increased risk of liver allograft rejection. *Transplantation* 2010; **89**: 222-226 [PMID: 20098286 DOI: 10.1097/TP.0b013e3181c3c2ff]

147 **Grancini V**, Resi V, Palmieri E, Pugliese G, Orsi E. Management of diabetes mellitus in patients undergoing liver transplantation. *Pharmacol Res* 2019; **141**: 556-573 [PMID: 30690071 DOI: 10.1016/j.phrs.2019.01.042]

148 **Lo C**, Jun M, Badve SV, Pilmore H, White SL, Hawley C, Cass A, Perkovic V, Zoungas S. Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients. *Cochrane Database Syst Rev* 2017; **2**: CD009966 [PMID: 28238223 DOI: 10.1002/14651858.CD009966.pub2]

149 **Davies MJ,** D'Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, Rossing P, Tsapas A, Wexler DJ, Buse JB. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetes Care* 2018; **41:** 2669-2701 [PMID: 30291106 DOI: 10.2337/dci18-0033]

150 **Unger LW**, Forstner B, Schneglberger S, Muckenhuber M, Eigenbauer E, Bauer D, Scheiner B, Mandorfer M, Trauner M, Reiberger T. Guideline-conform statin use reduces overall mortality in patients with compensated liver disease. *Sci Rep* 2019; **9**: 11674 [PMID: 31406146 DOI: 10.1038/s41598-019-47943-6]

151 **Krasnoff JB**, Vintro AQ, Ascher NL, Bass NM, Paul SM, Dodd MJ, Painter PL. A randomized trial of exercise and dietary counseling after liver transplantation. *Am J Transplant* 2006; **6**: 1896-1905 [PMID: 16889545 DOI: 10.1111/j.1600-6143.2006.01391.x]

152 **Zamora-Valdes D**, Watt KD, Kellogg TA, Poterucha JJ, Di Cecco SR, Francisco-Ziller NM, Taner T, Rosen CB, Heimbach JK. Long-term outcomes of patients undergoing simultaneous liver transplantation and sleeve gastrectomy. *Hepatology* 2018; **68**: 485-495 [PMID: 29457842 DOI: 10.1002/hep.29848]

**Footnotes**

**Conflict-of-interest statement:** LH, JE, GP and LWU declare no conflicts of interest related to this manuscript. TR received grant support from Abbvie, Boehringer-Ingelheim, Gilead, MSD, Philips Healthcare, Gore; speaking honoraria from Abbvie, Gilead, Gore, Intercept, Roche, MSD; consulting/advisory board fee from Abbvie, Bayer, Boehringer-Ingelheim, Gilead, Intercept, MSD, Siemens; and travel support from Abbvie, Boehringer-Ingelheim, Gilead and Roche.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Peer-review started:** January 24, 2021

**First decision:** March 7, 2021

**Article in press:**

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** Austria

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B


Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Kwan H **S-Editor:** Fan JR **L-Editor: P-Editor:**

**Figure Legends**



**Figure 1 Treatment recommendations based on liver fibrosis severity in metabolic dysfunction-associated fatty liver disease patients.** HCC: Hepatocellular carcinoma; MAFLD: Metabolic dysfunction-associated fatty liver disease; NASH: Non-alcoholic steatohepatitis.

**Table 1 Overview of important studies concerning the management of metabolic dysfunction-associated fatty liver disease/non-alcoholic steatohepatitis patients**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **Ref.** | **Study design** | **No. of patients** | **Liver disease** | **Main findings** |
| Diet/physical exercise | Berzigotti *et al*[57], 2017 | Prospective, uncontrolled | 60 (50 completed the study) | Cirrhosis, BMI ≥ 26 kg/m2, portal hypertension | Moderate exercise was safe in patients with compensated cirrhosis |
| Diet and moderate exercise reduced body weight and portal pressure |
| Weight loss ≥ 10% is associated with more pronounced portal pressure reduction |
| Wong *et al*[55], 2018 | Randomized controlled trial | 154 | NAFLD | Regular exercise associated with significantly more frequent remission of NAFLD (assessed by proton-magnetic MR-spectroscopy) |
| NAFLD remission in 67% of non-overweight patients (baseline BMI < 25 kg/m2) with lifestyle intervention |
| Dyslipidemia | Unger *et al*[150], 2019 | Retrospective | 1265 | CLD | 34.2% of non-advanced and 48.2% of advanced CLD patients did not receive guideline-conform statin therapy |
| Guideline-conform statin use was associated with improved overall survival in compensated, but not in decompensated CLD patients |
| Abraldes *et al*[69], 2009 | Randomized controlled trial | 59 | Cirrhosis and portal hypertension | Simvastatin reduced portal pressure (-8.3) in both patients, who did and did not also receive beta-blockers |
| Simvastatin improved liver perfusion |
| The effects of simvastatin were additive to beta-adrenergic blockade |
| Nelson *et al*[72], 2009 | Randomized controlled trial | 16 | NASH | Simvastatin reduced low-density lipoprotein by 26% |
| Simvastatin was well-tolerated |
| Simvastatin did not histologically improve NASH (but small sample size, only *n* = 10 follow-up biopsies) |
| T2DM | Lavine *et al*[108], 2011 | Randomized controlled trial | 173 | NAFLD | Sustained ALT level reduction was similar in the metformin and placebo group |
| Metformin did not change the NAFLD activity score |
| Cusi *et al*[102], 2016 | Randomized controlled trial | 101 | NASH and prediabetes/T2DM | Significantly more patients Significantly more patients receiving pioglitazone (59%) resolved NASH compared to placebo (23%) |
| Pioglitazone improved fibrosis score (-0.9 *vs* placebo 0.0) |
| Pioglitazone improved insulin sensitivity in liver, muscle and adipose tissue |
| Armstrong *et al*[104], 2016 | Randomized controlled trial | 52 | NASH | Significantly more patients receiving liraglutide (39%) resolved NASH compared to placebo (9%) |
| Significantly less patients receiving liraglutide (9%) exhibited fibrosis progression compared to placebo (36%) |
| Liraglutide was safe and well-tolerated |
| Bariatric surgery | Lassailly *et al*[114], 2015 | Prospective | 109 | NASH | NASH was resolved in 85% of patients one year after surgery and even in 94% with mild NASH before surgery (assessed *via* biopsy) |
| NASH persistence was higher in patients after gastric banding (30.4%) compared to gastric bypass (7.6%) |
| Goossens *et al*[117], 2016 | Retrospective | 59 | NASH | NASH is an independent predictor of overall mortality after bariatric surgery |
| NASH may reduce the overall survival benefit of bariatric surgery |
| Eilenberg *et al*[118], 2018 | Retrospective | 10 | NAFLD/NASH | Liver dysfunction, liver steatosis/fibrosis and cirrhosis may occur after bariatric surgery |
| Lengthening of the alimentary or common limb may lead to a clinical improvement in these patients |
| Post-LT | Krasnoff *et al*[151], 2006 | Randomized controlled trial | 151 | Post-LT | Exercise and dietary counseling intervention improved exercise capacity and self-reported general health |
| Adherence to the intervention was associated with positive trends in exercise capacity and body composition (% body fat) |
| Zamora-Valdes *et al*[152], 2018 | Prospective | 29 | NAFLD/NASH/obese ACLD | Patients, who received sleeve gastrectomy at the time of LT had more pronounced and sustained weight loss |
| They also had lower prevalences of hepatic steatosis, hypertension and insulin resistance 3 yr after LT |
| Patel *et al*[139], 2019 | Retrospective | 495 | Post-LT | Statins were underused after LT (54.3% of patients with known coronary artery disease did not receive statin therapy) |
| Statin use was well-tolerated |
| Statin therapy was associated with improved overall survival |

BMI: Body mass index; NAFLD: Non-alcoholic fatty liver disease; CLD: Chronic liver disease; NASH: Non-alcoholic steatohepatitis; ALT: Alanine aminotransferase; T2DM: Type 2 diabetes mellitus; LT: Liver transplantation; ACLD: Advanced chronic liver disease.